Brief: Onxeo completes enrollment in phase III study of Livatag for the treatment of hepatocellular carcinoma

Valerio Therapeutics SA

24/01/2017 17:31

Jan 24 (Reuters) - Onxeo SA  C4X.PA : 
    * Onxeo completes enrollment in phase III study of Livatag for the treatment of 
hepatocellular carcinoma 
    * Milestone completion in line with expected preliminary outcomes mid-2017 
    * To date, 390 patients have been randomized, with about 260 patients in Livatag(reg) 
treatment group and 130 in comparative group (best standard of care) 
 
Source text for Eikon:  ID:nNDLbfr9xm  
Further company coverage:  C4X.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))